2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1848

Adenosine A2A Receptor (A2AR) Stimulates Collagen Type III Synthesis Via β-Catenin Activation in Vitro and in Vivo

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster II

9:00AM-11:00AM: Abstract Number: 1737

Adherence to Subcutaneous Biological Therapies Among Inflammatory Arthropaty Patients from a University Hospital

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1430

Adherence to the International Consensus Quality Indicators for Longitudinal Health Maintenance and Preventative Care in a Pediatric Rheumatology Clinic

Quality Measures and Quality of Care - Poster II

9:00AM-11:00AM: Abstract Number: 1806

Adherence to Treatment and Social, Educational Levels in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1143

Adressing Medical Students’ Concerns in the Patient/Physician Interaction with People with Rheumatic and Musculoskeletal Diseases Leading to Handicap – a Pilot Experience Including Student Focus Groups and Interactions with Patient Associations

Education - Poster

9:00AM-11:00AM: Abstract Number: 1150

Advocacy 101: Engaging Rheumatology Fellows in Health Policy and Advocacy

Education - Poster

9:00AM-11:00AM: Abstract Number: 1823

African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in CD4+ T Cell and Monocyte Pathways

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1211

Allele-Dependent Binding of a Viral Protein to Autoimmune Disease-Associated Genetic Variants

Genetics, Genomics and Proteomics - Poster II

9:00AM-11:00AM: Abstract Number: 1230

Allopurinol Use and the Risk of Stroke in the Elderly

Health Services Research - Poster II

9:00AM-11:00AM: Abstract Number: 1389

Alterations in Nailfold Capillaroscopy in Childhood-Onset Systemic Lupus Erythematosus: The Role of Disease Activity in a Prospective Study

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 1788

Alterations in Sense of Smell and Limbic Structures in Patients with Systemic Lupus Erythematosus during 3-Years Follow-up

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

9:00AM-11:00AM: Abstract Number: 1571

Altered Bioenergetics, Mitochondrial Function and Pro-Inflammatory Pathways in RA Synovium in Response to Tofacitinib

Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster II

9:00AM-11:00AM: Abstract Number: 1130

Aminopeptidase N/CD13 Induces Monocyte Migration in Vitro and In Vivo and Signals through GPCR, Erk1/2, Jnk, Src, and NFκB

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster I

9:00AM-11:00AM: Abstract Number: 1867

An Abnormal Nailfold Capillaroscopy Pattern Is Common in Patients with Connective Tissue Disease and Is Associated with Pulmonary and Oesophageal Involvement, Even in the Absence of Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

9:00AM-11:00AM: Abstract Number: 1411

An Electronic MDHAQ (multidimensional health assessment questionnaire) Beyond an Electronic RAPID (routine assessment of patient index data): 21.3% of Rheumatoid Arthritis Patients Identified As Having Secondary Fibromyalgia Versus 3.5% By Clinicians

Quality Measures and Quality of Care - Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].